人附睾蛋白4在卵巢癌中的应用进展  

Application Progress of Human Epididymis Protein 4 in Ovarian Cancer

作　　者：师媛[1] 赵淑华[1] 张玲[1] 高露[1] 杨红[1] 

机构地区：[1]第四军医大学西京医院妇产科,陕西西安710032

出　　处：《现代生物医学进展》2017年第2期378-380,共3页Progress in Modern Biomedicine

基　　金：卫生部医药卫生科技发展研究中心基金项目(W2012FZ150)

摘　　要：卵巢癌是妇科常见的恶性肿瘤,其死亡率居妇科恶性肿瘤之首,早期发现有助于提高患者的五年生存率。人附睾蛋白(HE4)属于蛋白酶抑制剂家族,是一种新的卵巢癌肿瘤标志物。HE4在卵巢癌组织中及患者血清中处于高表达状态。研究表明在早期诊断方面HE4比糖类抗原125(CA125)有更高的灵敏度和特异度,在疾病的治疗过程中可以预测肿瘤细胞减灭术的满意度及患者对铂类的反应,在卵巢癌的复发及预后的监测中HE4也有很大的临床应用价值。Ovarian cancer,a commom femal malignant cancer, is the leading cause of death among gynecologic cancers. The early diagnosis make a contribute to improve the 5-year survival rate. Human epididymis protein 4（HE4）. A novel ovarian cancer marker, belonged to the family of protease inhibitor. HE4 is overexpressed in the tissue of ovarian tumor and serum of patients. HE4 has higher sensitivity and specificity than cancer antigen 125（CA125） in early diagnosis of ovarian cancer, and is a better predictor for optimal cytoreduction and platinum response during primary treatment. HE4 may have a great clinical value for detecting recurrences and monitoring the prognosis of ovarian cancer.

关 键 词：人附睾蛋白4 卵巢癌 诊断 预后 

分 类 号：R737.31[医药卫生—肿瘤]